학술논문
Antiseizure medication for brain metastasis-related epilepsy: Findings of optimal choice from a retrospective cohort.
Document Type
Academic Journal
Author
Sánchez-Villalobos JM; Department of Radiology and Physical Medicine, Faculty of Medicine/Dentistry, University of Murcia, Biomedical Research Institute of Murcia (IMIB-Arrixaca), Murcia, Spain; Department of Neurology, University Hospital Complex of Cartagena (Santa Lucia University Hospital - Santa María del Rosell University Hospital), Murcia, Spain. Electronic address: jmsvillalobos.nrl@gmail.com.; Aledo-Serrano Á; Epilepsy Program, Department of Neurology, Ruber International Hospital, Madrid, Spain.; Serna-Berna A; Department of Medical Physics and Radiation Protection, University Hospital Complex of Cartagena (Santa Lucia University Hospital - Santa María del Rosell University Hospital), Murcia, Spain.; Salinas-Ramos J; Department of Radiation Oncology, University Hospital Complex of Cartagena (Santa Lucia University Hospital - Santa María del Rosell University Hospital), Murcia, Spain.; Martínez-Alonso E; Department of Cell Biology and Histology, Faculty of Medicine/Dentistry, University of Murcia, Biomedical Research Institute of Murcia (IMIB-Arrixaca), Murcia, Spain.; Pérez-Vicente JA; Department of Neurology, University Hospital Complex of Cartagena (Santa Lucia University Hospital - Santa María del Rosell University Hospital), Murcia, Spain.; Alcaraz-Baños M; Department of Radiology and Physical Medicine, Faculty of Medicine/Dentistry, University of Murcia, Biomedical Research Institute of Murcia (IMIB-Arrixaca), Murcia, Spain.
Source
Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8703089 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-6844 (Electronic) Linking ISSN: 09201211 NLM ISO Abbreviation: Epilepsy Res Subsets: MEDLINE
Subject
Language
English
Abstract
Objective: To analyze the prevalence of antiseizure medication (ASM) in patients with brain metastasis-related epilepsy (BMRE) treated with radiosurgery and the relationship between ASM and psychiatric comorbidity.
Material and Methods: This is a cross-sectional observational design study with retrospective review of medical records of all patients with brain metastases treated with volumetric modulated arc therapy radiosurgery (VMAT-RS) between 2012 and 2018 in a tertiary oncology center. We included those patients with BMRE, analyzing the clinical and demographic data, with special attention to psychiatric comorbidities and the use of ASM.
Results: Of the 121 patients with brain metastases included for treatment with VMAT-RS, a total of 38 presented BMRE. The most widely used ASM as first-line treatment was levetiracetam (89%). Only 8% of the patients received sodium channel blockers. The most common psychiatric comorbidity was depression (42.1%).
Conclusions: Levetiracetam is the most widely used ASM in patients with BMRE treated with VMAT-RS. Nevertheless, common psychiatric comorbidities in this population might change the decision-making of ASM choice.
(Copyright © 2021 Elsevier B.V. All rights reserved.)
Material and Methods: This is a cross-sectional observational design study with retrospective review of medical records of all patients with brain metastases treated with volumetric modulated arc therapy radiosurgery (VMAT-RS) between 2012 and 2018 in a tertiary oncology center. We included those patients with BMRE, analyzing the clinical and demographic data, with special attention to psychiatric comorbidities and the use of ASM.
Results: Of the 121 patients with brain metastases included for treatment with VMAT-RS, a total of 38 presented BMRE. The most widely used ASM as first-line treatment was levetiracetam (89%). Only 8% of the patients received sodium channel blockers. The most common psychiatric comorbidity was depression (42.1%).
Conclusions: Levetiracetam is the most widely used ASM in patients with BMRE treated with VMAT-RS. Nevertheless, common psychiatric comorbidities in this population might change the decision-making of ASM choice.
(Copyright © 2021 Elsevier B.V. All rights reserved.)